CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$1.94 USD
-0.01 (-0.51%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.93 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CASI 1.94 -0.01(-0.51%)
Will CASI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Other News for CASI
12 Health Care Stocks Moving In Monday's Intraday Session
FDA Approves IND Application for CASI's CID-103, Advancing AMR Treatment
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft ...
Casi Pharmaceuticals announces FDA clearance of CID-103 IND application
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)